跳至主要内容
临床试验/NCT01690260
NCT01690260已完成1 期

Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.

Northern Orthopaedic Division, Denmark1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2004年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
41
试验地点
1
主要终点
Visible radiological signs of healing after 6 months.

研究概览

简要总结

Results of growth factors indicate that Bone Morphogenetic Proteins (BMP) have an exceptional ability to stimulate different characteristics of mesenchymale cells to osseous cells. Local application of BMP results in an increase of osseous tissue regardless of the location of the growth factor.

5 years clinical studies show that BMP's can stimulate an increase of osseous tissue and improve clinical results when autologous bone graft is reduced or removed.

The purpose of this study is to examine whether recombinant growth factor BMP-2 can replace autologous bone graft in order to stimulating ossification during transplantation of osseous tissue.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hospitalised for autologous bone graft based on Ilizarow treatment.
  • Age between 20 and 70 years.

排除标准

  • Rheumatoid osteoarthritis
  • Malignant disease
  • Current hormone treatment (glucocorticoid, parathyreoidea, thyreoidea)
  • Pregnancy
  • Abuse of drugs and alcohol
  • Need of long-term NSAID treatment
  • Breastfeeding women

研究组 & 干预措施

Bone Morphogenetic Protein 2

Experimental

Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.

干预措施: Bone Morphogenetic Protein 2 (Drug)

Bone Morphogenetic Protein 2

Experimental

Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.

干预措施: Autologous bone graft (Procedure)

Autologous bone graft

Experimental

Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.

干预措施: Bone Morphogenetic Protein 2 (Drug)

Autologous bone graft

Experimental

Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.

干预措施: Autologous bone graft (Procedure)

结局指标

主要结局

Visible radiological signs of healing after 6 months.

时间窗: An expected average of 6 months

Radiological signs of healing is a criteria for a successful result. Failure of healing after 6 months and/or a need for stimulant bone healing intervention can result in: * Dynamic measurement af immobilization * Ultrasound stimulation * Re-surgery with application of bone graft or bone replacement

次要结局

  • Change in serologic bone markers(An expected average of 6 months)

研究者

发起方
Northern Orthopaedic Division, Denmark
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验